Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach
2016 · BMC Infectious Diseases · 157 citations
https://doi.org/10.1186/s12879-016-1610-3
V
Vimalanand S. Prabhu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
106
Papers
1.5K
Citations
17
h-index
24
i10-index
Vimalanand S. Prabhu is an academic researcher from Merck & Co., Inc., Rahway, NJ, USA (United States). The author has contributed to research in topics: Endometrial and Cervical Cancer Treatments & Cervical Cancer and HPV Research & Ovarian cancer diagnosis and treatment. The author has an h-index of 17, co-authored 91 publications.
ORCID: 0000-0003-1358-8846Papers by this author
worksCost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
2018 · European Urology Oncology · 27 citations
https://doi.org/10.1016/j.euo.2018.09.009
Adjuvant and first line chemotherapy use for endometrial cancer
2022 · Gynecologic Oncology Reports · 15 citations
https://doi.org/10.1016/j.gore.2022.101002
The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
2021 · Cost Effectiveness and Resource Allocation · 13 citations
https://doi.org/10.1186/s12962-021-00328-x
Information needs during cancer care: qualitative research with advanced cervical cancer patients in Brazil, China, Germany, and the United States
2022 · Gynecologic Oncology Reports · 2 citations
https://doi.org/10.1016/j.gore.2022.101131
Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14635771
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat